Investigations Factors Affecting Formulation of Anastrozole As Nanostructured Lipid Carrier Publisher



Hashim AAJ¹ ; Rajab NA² ; Tekie FSM³ ; Dinarvand R³ ; Akrami M⁴ Show Affiliations
Source: International Journal of Pharmaceutical Research Published:2020

Abstract

Anastrozole (ANZ) is considered constitute of the fourth–generation of Non–steroidal aromatase blockage which uses in treatment of hormone receptor positive breast cancer in postmenopausal women used for 5 years. Nanostructured lipid carriers have recently emerged as a multifunctional platform for drug delivery in cancer therapy. In this study, we formulated ANZ as NLCs and evaluated in addition the impact of this formulation in induction of apoptosis and cellular uptake in MCF–7 breast cancer cells to improve patient compliance and decrease side effects. Formulas were prepared by homogenization plus ultrasonication technique, the 23 formulas were investigated for their particle size, polydispersity index, zeta potential. The mean particle size, polydispersity index, zeta potential, entrapment efficiency, loading capacity of the optimized formula (FP20) were found to be (85.9 nm), (0.229), (–41.1 mV), (97.4%) and (3.87%) respectively. The in–vitro drug release study demonstrated sustained releasing phase over a 48 hr. with an approximately (91.64 %) of the drug was released, with an anomalous release mechanism. Aim of this study to investigate factors affecting formulation as a new oral controlled and sustained release delivery system to offer an enhancing therapeutic effect and decrease side effects to improve patient compliance. © 2020, Advanced Scientific Research. All rights reserved.